Eli Lilly (NYSE:LLY) reported an indirect comparison suggesting that Foundayo 17.2 mg produced greater weight loss and A1C reduction than oral semaglutide 25 mg in adults with type 2 diabetes.
Lilly (NYSE:LLY) signed a definitive agreement to acquire Merida Biosciences for up to $2.875 billion in cash, adding precision biologics programs targeting autoimmune and allergic diseases.
Eli Lilly (NYSE:LLY) will present new clinical trial data on retatrutide, Foundayo (orforglipron), and eloraTZP at the European Association for the Study of Diabetes 2026 meeting in Milan from September 28 to October 2.
Eli Lilly and Company (NYSE:LLY) filed six lawsuits against U.S. businesses accused of selling black-market retatrutide products, while the company continues efforts to report illegal sales to regulators and law enforcement.
Eli Lilly (NYSE:LLY) received U.S. Food and Drug Administration approval on September 24, 2026, for Onswik, a once-weekly basal insulin treatment for adults with type 2 diabetes.
Eli Lilly (NYSE:LLY) received U.S. FDA approval for an expanded indication of Mounjaro (tirzepatide) to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high cardiovascular risk.
-640x360.webp&w=3840&q=75)
